Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symptoms and prolong survival. Based on the results of randomized trials, transcatheter aortic valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who are deemed 'inoperable'. Debatably, TAVI is also an alternative to SAVR in selected patients who are at high risk but operable. As we approach 10 years of clinical experience with TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and clinical outcomes with this rapidly evolving technology is appropriate.
Introduction
Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to functional deterioration, heart failure, and death. 1 Surgical aortic valve replacement (SAVR) is currently the standard of care and is generally accepted to alleviate symptoms and prolong survival, but 30% do not undergo SAVR. 2 However, since Dr Alain Cribier pioneered the first transcatheter aortic valve implantation (TAVI) procedure in 2002, 3 this relatively new technique has been used extensively in over 40 countries accumulating to .50 000 implantations. 4 -19 With results from the randomized Placement of AoRTic TraNscathetER Valves (PARTNER) trial, 20 TAVI is now the standard of care for extremely high risk or 'inoperable' patients and is a valid alternative to surgery for selected high-risk but 'operable' patients with symptomatic AS. 21 Currently, two different TAVI devices are widely used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA, USA) and the self-expanding Medtronic CoreValve TM (Medtronic, Minneapolis, MN, USA) ( Figure 1 ). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011. As we approach 10 years of clinical experience with TAVI, a review of the current literature and clinical outcomes is appropriate.
Initial experience
First-in-man, initial reports, and feasibility studies
Cribier and co-workers 3 performed the first TAVI in an inoperable patient in 2002 using a transeptal antegrade approach and a balloon-expandable aortic valve prosthesis, demonstrating the feasibility of percutaneous valve implantation. The antegrade approach Transcatheter aortic valve implantation was further explored, 22 coinciding with the first-in-man retrograde experience of a self-expanding prosthesis (CoreValve TM ). 23 Larger series quickly followed, with early experiences of small initiatives using both the balloon-expandable Cribier valve (Edwards Lifesciences Inc.) and the self-expandable CoreValve TM system. 9, 19 The devices showed a procedural success rate of 80%. After these single-centre experiences, several larger multicentre feasibility studies were initiated first in Europe and later in the USA. 6,24 -26 These studies showed that transapical (TA) and transfemoral (TF) TAVI in high-risk patients was feasible and could be performed with a high procedural success rate and a 30-day mortality of 10-15% ( Table 1) .
Registries Edwards registries
Several large European and Canadian registries have been published, showing excellent short-and mid-term results after TAVI using both the TF and TA devices. 12 
Mixed national registries
In 2011, results from four mixed CoreValve TM and Edwards European national registries have been reported, mostly using the TF and TA routes ( Table 2) . 4, 8, 29, 30 Overall, patients included in these registries were at high-risk according to surgical risk models; mean EuroSCORE 18-30%. These registries showed 1-year survival rates ranging between 71.9 and 81.6%. The UK registry reported the longest follow-up; survival was 73.7% at 2 years. 30 Several of these national initiatives performed access-route comparisons and reported that survival was generally higher in patients treated through the TF route. 4, 30 However, it should be noted that a transfemoral-first approach is often advocated, which may introduce selection bias and an unfair comparison between the two access routes. 31 Recently, the largest registry to date was reported by the FRANCE 2 (FRench Aortic National CoreValve and Edwards) investigators. 32 (Figure 2 ).
20,21
As the first of two parallel trials was completed, the results of PARTNER IB showed that TF TAVI was superior to standard therapy in patients not deemed candidates for surgery. 20 The primary endpoint of all-cause mortality was markedly reduced by 46% (P , 0.001). Recently reported 2-year outcomes showed continued encouraging results ( Figure 3A) . 33 At 2 years, the primary endpoint of all-cause mortality was reduced from 67.6% in the standard treatment arm to 43.3% in the TAVI arm (P , 0.001).
The PARTNER cohort IA compared TAVI with SAVR and met its non-inferiority endpoint: the all-cause 1-year mortality in the TAVI group was non-inferior to the SAVR group (24.2 vs. 26.8%; P ¼ 0.44; P ¼ 0.001 for non-inferiority). 21 Some concerns were raised with regard to neurologic events that were somewhat higher with TAVI than SAVR at 30 days (5.5 vs. 2.4%; P ¼ 0.04) and 1 year (8.3 vs. 4.3%; P ¼ 0.04). Although the recently published 2-year results showed that stroke rates were similar for TAVI and SAVR during 1 and 2 years with a hazard ratio of 1.22 (95% CI 0.67-2.23, P ¼ 0.52), the issue of stroke warrants further investigation and should not be underestimated ( Figure 3B and C ).
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The rate of the composite of all-cause death and stroke was encouragingly nearly identical after TAVI (37.1%) and SAVR (36.4%) at 2 years (P ¼ 0.85).
Ongoing trials
In the USA, a randomized trial is currently ongoing to evaluate the safety and efficacy of the Medtronic CoreValve TM in the treatment of severe symptomatic AS in patients at high or extreme risk for SAVR (ClinicalTrials.gov Identifier: NCT01240902). The trial consists of two arms. Patients in a high-risk arm will be randomized between SAVR and TAVI; the primary endpoint consists of allcause mortality at 1 year. An extreme risk arm will function as an observational arm in which a composite of all-cause mortality and major stroke is the primary endpoint.
As a sequel to the PARTNER I trial, a second randomized trial (PARTNER II) is currently ongoing. It was designed to investigate the performance and outcomes after TAVI with the nextgeneration Edwards SAPIEN XT valve, model 9300TFX, as well as the new low-profile 18-Fr NovaFlex TM delivery catheter in patients deemed non-operable (ClinicalTrials.gov Identifier: NCT01314313) ( Figure 4A ). Given the results of the control arm in PARTNER IB, it has been judged that a study comparing TAVI against a 'medical management' control group is no longer ethical. 35 Consequently, an 'old device' vs. 'new device' noninferiority trial was designed. Enrolment began in January 2011 and it is anticipated that primary endpoint results will be published mid-2013. In Denmark, a phase 2 randomized trial evaluating TAVI in patients ≥70 years of age started enrolment in December 2009 (ClinicalTrials.goc identifier: NCT01057173). The trial will randomize a total of 280 patients to TAVI (n ¼ 140) and SAVR (n ¼ 140). The primary endpoint is the composite of all-cause death, myocardial infarction, and stroke at 1 year and is scheduled to be completed late 2013. In an attempt to expand the indication of TAVI to lower-risk patients, the PARTNER IIA trial will be randomizing patients between TAVI with the SAPIEN XT valve and SAVR in intermediate risk patients (ClinicalTrials.gov Identifier: NCT01314313) ( Figure 4A) . Similarly, the prospective randomized, international SURTAVI trial will randomize 1900 intermediate risk patients between TAVI with the Medtronic CoreValve TM and SAVR at 80 centres throughout the USA, Canada, Europe, and Australia (ClinicalTrials.gov Identifier: NCT01586910) ( Figure 4B ).
Cost-effectiveness
Since TAVI has been shown to be superior to standard medical therapy and non-inferior to SAVR and is increasingly being used in current practice, the incremental costs and cost-effectiveness of this therapy warrant evaluation.
In the PARTNER IB trial, the mean cost for TF TAVI was $42 806 which accumulated to $78 542 for the initial hospitalization and $106 076 at 1 year. 36 Compared with medical therapy, Therefore, TA TAVI was found to be a less attractive alternative to SAVR, although this conclusion has been somewhat criticized because the analysis was not powered and operators were little experienced. 31 
Alternative access sites
Like the TA approach, a subclavian approach allows patients with unfavourable iliofemoral anatomy or extensive disease to be treated with TAVI. Petronio et al. 13 recently reported a series of 54 patients, showing a procedural success rate of 100%, a procedural mortality of 0, a 30-day mortality of 0%, and 6-month mortality of 9.4%. No specific vascular complications for subclavian access were reported. The subclavian approach is usually performed with the self-expanding CoreValve TM system and can be fully percutaneous. 37 Recently, a transaortic approach with direct access to the ascending aorta though an anterior minithoracotomy has been advocated. Access is gained through a J-shaped partial upper sternotomy or using a small right thoracotomy through the intercostal space. Avoidance of LV apical injury or inadequate healing along with reduction in post-operative pain and its associated impairment of respiratory dynamics are potential advantages of this novel approach. Encouraging results have been published from Adapted with permission from Kodali and colleagues. 34 small series using both devices. 38, 39 It may be suitable for patients with unfavourable iliofemoral and subclavian anatomy and in whom a TA approach is considered too risky (chest deformity, severe respiratory disease or low ejection fraction). Also, TAVI via the carotid artery has been proposed. In such cases, it is crucial to evaluate the cerebral arteries, carotid and vertebral arteries, and circle of Willis, to assess the risk of ischaemic stroke. 40 
Valve-in-valve for failing bioprostheses
Since 2007, when the first TAVI was implanted in a failing surgical aortic bioprosthesis in order to avoid redo surgery, interest in this concept has grown and feasibility and safety have been established. 41 , 42 Piazza and colleagues 43 published a series of 20 patients (mostly TA: 16/20) and reported successful implantation in 18 of 20 patients and in-hospital mortality in 3 patients. Indeed, transcatheter heart valves have also been implanted in failing mitral prostheses or even annuloplasty rings, and failing tricuspid prostheses, expanding the potential use of devices originally developed for the aortic position. 44, 45 Knowledge of the basic construction, dimensions, and potential failure modes of the surgical bioprostheses is of paramount importance for this technique to succeed. Various complications such as coronary obstruction and device embolization may be implicated with certain surgical bioprostheses but not others. 46 Also, small surgical bioprostheses (e.g. 19 mm) may not respond well to valve-in-valve implantation because of device constraint within the rigid bioprosthesis and incomplete stent expansion, frequently leading to prosthesis -patient mismatch. 47, 48 The presence of a functioning mitral prosthesis may further complicate device delivery, although a recent report has shown that optimal valve positioning through a TA approach should be technically achievable with modifications of the 'classic' procedure. 49 
Efficacy and long-term outcomes Symptom improvement
Improvement in cardiac symptoms and functional class has been reported at short-and medium-term after TAVI. 14, 18, 20, 21, 50 However, functional assessment of the population currently eligible for and treated with TAVI is difficult, mainly because of their multiple co-morbidities. 51 Three-year follow-up data have been published and are consistent with lasting improvement in cardiac symptoms. 52 While 86% of patients were in NYHA class III or IV at baseline, 93% of surviving patients were in NYHA class I/II at 3-year follow-up. Similarly, the PARTNER trial showed that patients treated with TAVI compared with patients treated with standard medical therapy have better symptom control at 1 year. 20 Indeed, the 1-year rate of NYHA class III or IV was 25.2% for the TAVI group compared with 58.0% for the standard medical therapy group (P , 0.001).
Valve durability and haemodynamic performance
TAVI has demonstrated excellent immediate and short-term durability of the prosthesis that is comparable to SAVR, sustaining to 3 years. 14, 15, 18, 20, 27, 34, 52 Actually, data suggest that transcatheter heart valves have greater valve areas and lower gradients than surgical bioprostheses ( Figure 5) , 34, 53 which could reduce the prevalence of prosthesis-patient mismatch. 54 For both the Edwards SAPIEN and Medtronic CoreValve TM there was no evidence of structural or non-structural valvular deterioration, stent fracture, deformation, or valve migration.
Predictors
As emphasized throughout the manuscript, many of the listed complications are predictors of short-term and/or long-term mortality. As current randomized trials are moving towards evaluating TAVI in a lower-risk patient population (SURTAVI, PARTNER 2) with a longer life expectancy, prediction of mid-and long-term outcomes (≥1 year) will become increasingly important. Some predictors should be similar to the surgical literature, but the mounting TAVI experience has shown that the incidence and ratio may vary significantly between the two therapies. For example, paravalvular leakage is more common after TAVI than after SAVR and has been identified as a potential significant predictor for long-term mortality.
34 Table 3 provides a summary of independent predictors of mortality that have been identified in previous studies. Due to the relative infancy of TAVI and the lack of large databases for SAVR, 55 it is likely that additional predictors will come to light over the years. Furthermore, accurate hazard ratios of predictors cannot be given at the current time, due to the severe heterogeneity between studies.
Lessons learned Patient selection
One of the critical aspects of TAVI we have learned so far is that patient selection is crucial but cumbersome due to inaccuracy of current risk models to predict outcomes in high-risk patients. 56 Several variables that have shown to be predictive are not Figure 5 Two-year time trends in haemodynamics after TAVI vs. SAVR. Adapted with permission from Kodali and colleagues. 34 included, such as frailty, liver disease, and the presence of a porcelain aorta. Decision making should therefore not be based exclusively on clinical risk scores. Instead, it is accepted that the heart team can better judge patient eligibility for TAVI or SAVR. Such a team is dynamic and can include general cardiologists, interventional cardiologists, surgeons, imaging specialists, neurologists, anaesthesiologists, geriatricians, and other specialists. 57, 58 Besides the decision to treat by means of TAVI or SAVR, one must consider multiple access approaches. Frequently, a 'transfemoral-first' attitude is advocated and comprehensive screening of the peripheral arteries and aorta by angiography or preferably by multislice CT-scan (MSCT), is necessary to assess feasibility. 59 MSCT also allows for evaluation of left ventricular dimensions and function, and other potential diseases (e.g. coronary artery disease), which can further help to contemplate feasibility, safety, and efficacy.
Sizing
Accurate preoperative annular sizing is one of the main predictors of a successful TAVI procedure. Several modalities have been proposed for accurate sizing. At first, trans-thoracic and/or transoesophageal echocardiography were used to decide which size valve would best be implanted to achieve procedural success with limited or no residual para-valvular aortic regurgitation.
More recently, the use of three-dimensional and even fourdimensional MSCT has been shown to be most effective in sizing for TAVI. 60, 61 In contrast to trans-esophageal echocardiography, it is non-invasive and has a high reproducibility. 62 Recent studies have shown that the area-derived diameter and basal ring average diameter of the annulus are the most suitable measurements for valve-sizing. Nevertheless, oversizing of the transcatheter heart valve in relation to the annulus size remains necessary to obtain procedural success with limited aortic regurgitation.
Learning curve
Understanding the importance of patient selection, utilizing better anatomical screening to clarify both the aortic root and iliofemoral geometry, and the development of new devices have led to notable improvements in outcome over time. A report highlighting the importance of the learning curve in 270 patients showed that procedural experience was an independent predictor of 30-day survival. 63 Furthermore, the procedural success rate has significantly increased ( Figure 6) and 30-day mortality (B) after TAVI. Data from Gurvitch and colleagues. 63 
